AKBA
AKEBIA THERAPEUTICS, INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $1.11 | $1.01 | -9% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.35 | $1.01 | -25% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $1.35 | $1.01 | -25% |
| Two Sigma Investments re-entered | Q4 2024(8Q snapshot) | 6Q | $1.86 | $1.01 | -46% |
| D.E. Shaw | Q4 2024(8Q snapshot) | 6Q | $1.86 | $1.01 | -46% |
| AQR Capital Management | Q4 2024(8Q snapshot) | 6Q | $1.86 | $1.01 | -46% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q2 2025 | Q4 2025 | → $1.67 | -34% |
| Maverick Capital 2× in & out | Q4 2021 | Q1 2022 | → $1.74 | -39% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Akebia Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001635046-26-000005Apr 3, 2026
- Form 40001591467-26-000003Mar 5, 2026
- Form 40002007730-26-000002Feb 4, 2026
- Form 40001661887-26-000002Feb 4, 2026
- Form 40001619834-26-000002Feb 4, 2026
- Form 40002107264-26-000006Feb 4, 2026
- Form 40001762507-26-000002Feb 4, 2026
- Form 40001591467-26-000002Feb 4, 2026
- Form 40001661887-26-000001Feb 3, 2026
- Form 40001619834-26-000001Feb 3, 2026
- Form 40002107264-26-000005Feb 3, 2026
- Form 40002007730-26-000001Feb 3, 2026
- Form 40001762507-26-000001Feb 3, 2026
- Form 40001591467-26-000001Feb 3, 2026
- Form 40001562180-25-005201Jul 1, 2025
Fundamentals
XBRL · AKEBIA THERAPEUTICS, INC.Annual figures sourced directly from AKEBIA THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Akebia Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 28, 2026
- 8-KMaterial eventApr 1, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventJan 30, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 1, 2025
- 8-KMaterial eventNov 17, 2025
- 10-QQuarterly reportNov 10, 2025
- 8-KMaterial eventNov 10, 2025
- 8-KMaterial eventOct 28, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q1 2026 | open | $1.20 | $1.01 | -16% |
| Point72 Asset Management | Q2 2025 | Q4 2025 | $2.54 | $1.67 | -34% |
| Citadel Advisors | Q1 2025 | open | $2.13 | $1.01 | -53% |
| Two Sigma Investments | Q4 2024 | Q1 2025 | $1.86 | $2.13 | +15% |
| D.E. Shaw | Q4 2024 | open | $1.86 | $1.01 | -46% |
| AQR Capital Management | Q4 2024 | open | $1.86 | $1.01 | -46% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $1.35 | $1.86 | +38% |
| Millennium Management | Q3 2024 | open | $1.35 | $1.01 | -25% |
| Renaissance Technologies | Q3 2024 | open | $1.11 | $1.01 | -9% |
| Maverick Capital | Q4 2021 | Q1 2022 | $2.87 | $1.74 | -39% |
| Maverick Capital | Q2 2021 | Q3 2021 | $3.41 | $2.43 | -29% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.